What separates them is what they were specifically built and validated to do, and that distinction is what determines which one is right for which patient
In patients with rhabdomyosarcomatous differentiation, the 2- and 5-year survival rates are 15% and 11%, respectively
Gao X et al
Research demonstrates BPC-157 increases mesenchymal cell recruitment with periosteum reactivation occurring within 3 days of treatment initiation, establishing conditions favorable for rapid bone repair
However, we did not observe significant differences in circulating IGF-1 levels with mAb treatment in older mice, though levels tended to be higher in mAb-treated females, but glucose homeostasis was not adversely affected in either sex, suggesting minimal disruption of the somatotropic axis in this older cohort of mice
New England Journal of Medicine, 384(11), 9891002.